Predict your next investment

Immusoft company logo
Corporation
HEALTHCARE | Biotechnology
immusoft.com

See what CB Insights has to offer

Total Raised

$36.83M

Investors Count

13

Deal Terms

2

Immusoft Funding, Immusoft Valuation & Immusoft Revenue

9 Fundings

Immusoft's latest funding round was a Grant - II for $0.47M on September 25, 2020.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/25/2020

Grant - II

$0.47M

Undisclosed Investors

$0.00B

((9.99x))

FY 1234

1

9/23/2020

Unattributed VC

$99M

$0.00B

((9.99x))

FY 1234

10

4/13/2020

Loan

$99M

$0.00B

((9.99x))

FY 1234

10

1/3/2019

Series B - II

$99M

$0.00B

((9.99x))

FY 1234

10

1/5/2018

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

Date

9/25/2020

9/23/2020

4/13/2020

1/3/2019

1/5/2018

Round

Grant - II

Unattributed VC

Loan

Series B - II

Series B

Amount

$0.47M

$99M

$99M

$99M

$99M

Investors

Undisclosed Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

1

10

10

10

10

Immusoft Deal Terms

2 Deal Terms

Immusoft's deal structure is available for 2 funding rounds, including their Series B from January 05, 2018.

Round

Series B

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

Immusoft Investors

13 Investors

Immusoft has 13 investors. Mesa Verde Venture Partners invested in Immusoft's Unattributed VC funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/3/2019

9/23/2020

2
Series B - II, Unattributed VC (2020)

Venture Capital

California

1/3/2019

9/23/2020

2
Series B - II, Unattributed VC (2020)

Venture Capital

California

4/13/2020

4/13/2020

1
Loan

Government

DC

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporate Venture

California

First funding

1/3/2019

1/3/2019

4/13/2020

00/00/0000

00/00/0000

Last Funding

9/23/2020

9/23/2020

4/13/2020

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

2
Series B - II, Unattributed VC (2020)
2
Series B - II, Unattributed VC (2020)
1
Loan

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Venture Capital

Government

Venture Capital

Corporate Venture

Location

California

California

DC

California

California

Immusoft Acquisitions

1 Acquisition

Immusoft acquired 1 company. Their latest acquisition was Discovery Genomics on March 08, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/8/2016

Acquired

1

Date

3/8/2016

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.